source
- Novo says launch of obesity drug CagriSema in Europe delayed by a couple of yearsNovo Nordisk announced it will not bring its obesity candidate CagriSema to European markets for the next few years. The statement came from the company's outgoing chief financial officer, Karsten…
- Flagship partner Louisa Helms credits high-school librarian for sparking biotech careerLouisa Helms, a BioSpace 40 Under 40 honoree and partner at Flagship Pioneering, reflects on a unique path into biotech. In high school she was mentored by librarian Tammy Carabello, who turned th…